EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Validity of the ROX Index and APACHE II in Predicting Early, Late, and Non-Responses to Non-Invasive Ventilation in Patients with COVID-19 in a Low-Resource Setting

Sumalatha Arunachala iD, Ashwaghosha Parthasarathi iD, Chetak Kadabasal Basavaraj iD, Mohammed Kaleem Ullah iD, Shreya Chandran, Hariharan Venkataraman, Prashant Vishwanath, Koustav Ganguly iD, Swapna Upadhyay iD, Padukudru Anand Mahesh iD

Viruses · 2023

DOI: 10.3390/v15112231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Sumalatha Arunachala und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, India. Hauptthemen laut MEDLINE: Noninvasive Ventilation, COVID-19, Pneumonia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, NIH HHS, National Institute of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of the Ratio of Oxygen Saturation (ROX) index to predict the success of high-flow nasal oxygenation (HFNO) is well established. The ROX can also predict the need for intubation, mortality, and is easier to calculate compared with APACHE II. In this prospective study, the primary aim is to compare the ROX (easily administered in resource limited setting) to APACHE II for clinically relevant outcomes such as mortality and the need for intubation. Our secondary aim was to identify thresholds for the ROX index in predicting outcomes such as the length of ICU stay and failure of non-invasive respiratory support therapies and to assess the effectiveness of using the ROX (day 1 at admission, day 2, and day 3) versus Acute physiology and chronic health evaluation (APACHE) II scores (at admission) in patients with Coronavirus Disease 2019 (COVID-19) pneumonia and Acute Respiratory Distress Syndrome (ARDS) to predict early, late, and non-responders. After screening 208 intensive care unit patients, a total of 118 COVID-19 patients were enrolled, who were categorized into early (n = 38), late (n = 34), and non-responders (n = 46). Multinomial logistic regression, receiver operating characteristic (ROC), Multivariate Cox regression, and Kaplan–Meier analysis were conducted. Multinomial logistic regressions between late and early responders and between non- and early responders were associated with reduced risk of treatment failures. ROC analysis for early vs. late responders showed that APACHE II on admission had the largest area under the curve (0.847), followed by the ROX index on admission (0.843). For responders vs. non-responders, we found that the ROX index on admission had a slightly better AUC than APACHE II on admission (0.759 vs. 0.751). A higher ROX index on admission [HR (95% CI): 0.29 (0.13–0.52)] and on day 2 [HR (95% CI): 0.55 (0.34–0.89)] were associated with a reduced risk of treatment failure. The ROX index can be used as an independent predictor of early response and mortality outcomes to HFNO and NIV in COVID-19 pneumonia, especially in low-resource settings, and is non-inferior to APACHE II.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Noninvasive VentilationCOVID-19PneumoniaHumansAPACHEProspective StudiesPrognosisRetrospective Studies

Stichwörter der Autor:innen

APACHE IICOVID-19HFNONIVROX indexhigh-flow nasal oxygenationintensive care unitnon-invasive ventilation

Autor:innen und Institutionen

  • Department of Respiratory Medicine, JSS Medical College, JSS Academy of Higher Education and Research, Mysuru 570015, India.
  • Public Health Research Institute of India, Mysuru 570020, India.
  • Department of Critical Care Medicine, Adichunchanagiri Institute of Medical Sciences, Bellur 571448, India.
  • Allergy, Asthma, and Chest Centre, Krishnamurthypuram, Mysuru 570004, India.
  • Rutgers Centre for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ 08901, USA.
  • Centre for Excellence in Molecular Biology and Regenerative Medicine (A DST-FIST Supported Center), Department of Biochemistry (A DST-FIST Supported Department), JSS Medical College, JSS Academy of Higher Education and…

ORCID-Profile: Sumalatha Arunachala, Ashwaghosha Parthasarathi, Chetak Kadabasal Basavaraj, Mohammed Kaleem Ullah, Koustav Ganguly, Swapna Upadhyay, Padukudru Anand Mahesh

Förderung

  • FIC NIH HHS
  • NIH HHS
  • National Institute of Health (NIH)
  • The Wellcome Trust DBT India Alliance
  • Swedish Heart-Lung Foundation

Zitieren

APA

Arunachala, S., Parthasarathi, A., Basavaraj, C. K., Kaleem Ullah, M., Chandran, S., Venkataraman, H., Vishwanath, P., Ganguly, K., Upadhyay, S., & Mahesh, P. A. (2023). The Validity of the ROX Index and APACHE II in Predicting Early, Late, and Non-Responses to Non-Invasive Ventilation in Patients with COVID-19 in a Low-Resource Setting. Viruses. https://doi.org/10.3390/v15112231

Vancouver

Arunachala S, Parthasarathi A, Basavaraj CK, Kaleem Ullah M, Chandran S, Venkataraman H, et al. The Validity of the ROX Index and APACHE II in Predicting Early, Late, and Non-Responses to Non-Invasive Ventilation in Patients with COVID-19 in a Low-Resource Setting. Viruses. 2023. doi:10.3390/v15112231

BibTeX
@article{Arunachala2023,
  author = {Arunachala, Sumalatha and Parthasarathi, Ashwaghosha and Basavaraj, Chetak Kadabasal and Kaleem Ullah, Mohammed and Chandran, Shreya and Venkataraman, Hariharan and Vishwanath, Prashant and Ganguly, Koustav and Upadhyay, Swapna and Mahesh, Padukudru Anand},
  title = {The Validity of the ROX Index and APACHE II in Predicting Early, Late, and Non-Responses to Non-Invasive Ventilation in Patients with COVID-19 in a Low-Resource Setting},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15112231}
}
Kostenlos starten →